RVMD’s Near-100% Year-To-Date Rally Sparks Valuation Debate: Has the Stock Gotten Too Pricy? Jun 5, 2026 Life Science
Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities Jun 4, 2026 Life Science
Moderna Outshines Pharma Giants Lilly, Merck and Pfizer With 43% Year-to-Date Surge Jun 3, 2026 Life Science
5 Institutional-Approved High-Dividend Pharmaceutical Stocks for Passive Income Investors May 29, 2026 Life Science
Beyond Lilly and Novo Nordisk: Two Under-the-Radar Picks in the Obesity Drug Market May 26, 2026 Life Science
Why Eli Lilly Is Underrated in the Red-Hot GLP-1 Weight-Loss Drug Race, per Morgan Stanley May 25, 2026 Life Science
Pfizer’s 50% Stock Crash: A Hidden Contrarian Buy Amid Booming Healthcare Sector May 22, 2026 Life Science
Can Viking Therapeutics Replicate Eli Lilly’s Success in the Weight-Loss Drug Market? May 21, 2026 Life Science
With the Macroeconomic Environment Improving, these Three Biotech Stocks Are Worth Watching May 21, 2026 Life Science
Dyne Therapeutics Stock Rises 40% in a Year, but Saturn V Fund Reduces Holdings May 20, 2026 Life Science
Bullish on Oncology Drug Potential? This Biotech Fund Increases Stake in Enliven Therapeutics May 13, 2026 Life Science
Can Novo Nordisk Stage a Turnaround on Wegovy Data and Robust Drug Pipeline? May 13, 2026 Life Science
Pfizer’s 6.7% Dividend: Can It Survive Plunging Profits and Cash Flow Crunch? May 12, 2026 Life Science
